Sumatriptan needle-free injectable - Glide/Endo

Drug Profile

Sumatriptan needle-free injectable - Glide/Endo

Alternative Names: Glide sumatriptan; GP-01; Sumatriptan SDI

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator Glide Pharma
  • Developer Endo International; Glide Technologies
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 17 Mar 2011 Phase-II clinical trials in Migraine in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top